Keros Therapeutics Stock News

LEXINGTON, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commerci

LEXINGTON, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercia

Keros Therapeutics, Inc. (KROS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

KROS is a small company with three clinical programs. Surprisingly, each program has clinical data.

Keros is a pre-revenue biotech with two therapies in phase 2 trials. The company focuses on treatments for blood and musculoskeletal disorders.

Keros Therapeutics (KROS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

LEXINGTON, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commerc

Data is promising for KROS' KER-050 compound; investors are rewarding the company on its novel hypotheses. We performed a deep dive on its most recent readouts on KER-050.

LEXINGTON, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commerci

Keros Therapeutics, Inc. (KROS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

LEXINGTON, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commerci

Keros Therapeutics, Inc. (KROS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

A sympathetic reaction to a competitor's drug helped push the clinical-stage pharmaceutical company's shares higher.

LEXINGTON, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2021.

Related Stocks: ATRC , KROS , BCYC , CDXS , PFE , MEIP , BLU , FNA , NGM , MRTX , CRNX , PLRX , ALDX , XBI , YMAB , STIM , APTO , WW ,